Extended indication

Extension of indication to include the use of belatacept in conversion from a calcinerin inhibitor -

Therapeutic value

No judgement

Registration phase

Registration application pending

Product

Active substance

Belatacept

Domain

Chronic immune diseases

Reason of inclusion

Indication extension

Main indication

Other chronic immune diseases

Extended indication

Extension of indication to include the use of belatacept in conversion from a calcinerin inhibitor -based regimen to a belatacept-based regimen post transplantation.

Proprietary name

Nulojix

Manufacturer

BMS

Route of administration

Intravenous

Therapeutical formulation

Intravenous drip

Budgetting framework

Intermural (MSZ)

Registration

Registration route

Centralised (EMA)

Type of trajectory

Normal trajectory

Submission date

August 2020

Expected Registration

June 2021

Orphan drug

No

Registration phase

Registration application pending

Therapeutic value

Therapeutic value

No judgement

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

Additional comments
NULOJIX, 250 mg POEDER VOOR OPLOSSING VOOR INFUSIE 250MG 	€ 483,04.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.